RxDoctor Payments Data

Linsey Spence, DO

Gastroenterology · Charlotte, NCNPI 1447660840

Payments from drug & device makers

$3,996in general payments, 2019–2025

Across 28 payments — averaging $142.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Boston Scientific$2K
  • Apollo Endosurgery US Inc$175
  • Pfizer$114
  • Olympus America Inc.$33
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
  • plus $17 from 1 others

What the payments were for

  • Speaking & faculty fees$1,27132%
  • Travel & lodging$1,53438%
  • Food & beverage$1,19130%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,996 in reported general payments places this provider in the 55th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$188,783
Medicare patients
342
Services billed
8,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide90$4,167,311
MytesiCrofelemer17$41,490
MotegrityPrucalopride Succinate32$22,286
TrulancePlecanatide13$7,376
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C48$6,945
Lansoprazole12$4,545
Lactated RingersRinger's Solution,lactated61$4,333
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag34$4,266
Colestipol Hcl18$3,411
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates48$3,280
Pantoprazole Sodium80$2,655
Esomeprazole Magnesium15$2,529
Famotidine61$2,461
LoperamideLoperamide Hcl32$1,652
Sucralfate22$1,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex, Motegrity$1,912$4,189,597122 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$18$14,32161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →